BioCentury
ARTICLE | Clinical News

Avax begins Phase II

January 18, 2000 8:00 AM UTC

AVXT began the first of three planned U.S. Phase II trials of its O-Vax haptenized autologous cell vaccine to treat advanced ovarian cancer. It expects to enroll more than 400 patients in the trials. ...